Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glaukos Corp (NY: GKOS )

126.94 +4.63 (+3.79%)
Streaming Delayed Price Updated: 1:00 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corp

< Previous 1 2 3 4 5 6 7 8 Next >
Glaukos Corp (GKOS) FY 2021 Earnings Call Transcript
GKOS earnings call for the period ending November 29, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
FDA Clears Sight Sciences' Trial Of Canaloplasty Combined With Cataract Surgery To Lower Ocular Pressure
The FDA has signed off Sight Sciences Inc's (NASDAQ: SGHT) clinical study to assess investigational higher volume OMNI device to perform canal viscodilation... 
Via Benzinga
Exposures Product Safety
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Academy of Ophthalmology Annual Meeting
From Glaukos Corporation
Via Business Wire
Glaukos Corp (GKOS) Q3 2021 Earnings Call Transcript
GKOS earnings call for the period ending October 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Glaukos Corporation Announces Third Quarter 2021 Financial Results
From Glaukos Corporation
Via Business Wire
Why Glaukos Stock Is Soaring Today
CMS' final payment rates for 2022 spurred an analyst upgrade for Glaukos. 
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers iRhythm Technologies (NASDAQ:IRTC) stock moved upwards by 52.78% to $117.34 during Wednesday's regular session. iRhythm Technologies's stock is trading at... 
Via Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
Why Are Glaukos Shares Rallying Today?
Glaukos Corporation (NYSE: GKOS) shares have gained as investors cheer the final physician payment rates and outpatient facility fees issued by the Centers for Medicare... 
Via Benzinga
86 Biggest Movers From Yesterday
Gainers FAT Brands Inc. (NASDAQ: FATBB) shares gained 99.2% to settle at $15.44. FAT Brands recently announced plans to acquire Fazoli’s Restaurant Chain for $130 million.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2021
Upgrades Benchmark upgraded the previous rating for Devon Energy Corp (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, trader! We're starting the day off right with a dive into the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
25 Stocks Moving in Wednesday's Pre-Market Session
Gainers Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 56.4% to $26.20 in pre-market trading on the heels of three new announcements from the company outlining strategic plans to... 
Via Benzinga
Glaukos Corporation to Release Third Quarter 2021 Financial Results after Market Close on November 4
From Glaukos Corporation
Via Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 European Society of Cataract and Refractive Surgeons Annual Meeting
From Glaukos Corporation
Via Business Wire
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.
From Glaukos Corporation
Via Business Wire
Ivantis To Pay $60M In Patent Litigation Settlement With Glaukos
Glaukos Corp (NYSE:GKOS) has 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.
From Glaukos Corporation
Via Business Wire
Glaukos Files Pre-Market Application For Intraocular Pressure Device
Glaukos Corp (NYSE: GKOS) has submitted a supplemental premarket approval (PMA) application to the FDA for its iStent infinite Trabecular Micro-Bypass System.... 
Via Benzinga
Exposures Product Safety
Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent infinite™
From Glaukos Corporation
Via Business Wire
Return on Capital Employed Overview: Glaukos
Pulled from Benzinga Pro data Glaukos (NYSE:GKOS) reported Q2 sales of $78.09 million. Earnings fell to a loss of $14.22 million, resulting in a 20.47% decrease from last quarter... 
Via Benzinga
Glaukos Announces Participation in the Wells Fargo Healthcare Conference
From Glaukos Corporation
Via Business Wire
Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent® Technologies
From Glaukos Corporation
Via Business Wire
Glaukos Guided Below Consensus After Q2 Earnings; Analysts Cut Price Target
Glaukos Corporation (NYSE:GKOS) 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.